Cargando…

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study

BACKGROUND: Prognostic value or clinical implications of fluid status monitoring in liver cirrhosis are not fully elucidated. Tolvaptan, an orally available, selective vasopressin V2-receptor antagonist approved for hyponatremia in the United States and European Union. It is also used for cirrhotic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiba, Shunsuke, Chu, Po-sung, Nakamoto, Nobuhiro, Yamataka, Karin, Taniki, Nobuhito, Ojiro, Keisuke, Yamaguchi, Akihiro, Morikawa, Rei, Yoshida, Aya, Ikura, Akihiko, Ebinuma, Hirotoshi, Saito, Hidetsugu, Kanai, Takanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059268/ https://www.ncbi.nlm.nih.gov/pubmed/32138675 http://dx.doi.org/10.1186/s12876-020-01205-2

Ejemplares similares

CLIF‐C Organ Failure Score and Liver Volume Predict Prognosis in Steroid‐Treated Severe Acute Autoimmune Hepatitis
por: Ikura, Akihiko, et al.
Publicado: (2020)

On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C
por: Chu, Po-sung, et al.
Publicado: (2017)

Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis
por: Hoshi, Hitomi, et al.
Publicado: (2021)

Liver Fibrosis Markers Improve Prediction of Outcome in Non‐Acetaminophen‐Associated Acute Liver Failure
por: Ugamura, Aya, et al.
Publicado: (2018)

Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts
por: Yamataka, Karin, et al.
Publicado: (2022)

Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/ Ribavirin Therapy in Chronic Hepatitis C
por: Chu, Po-sung, et al.
Publicado: (2015)

Bone marrow-derived macrophages distinct from tissue-resident macrophages play a pivotal role in Concanavalin A-induced murine liver injury via CCR9 axis
por: Amiya, Takeru, et al.
Publicado: (2016)

Acetaldehyde exposure underlies functional defects in monocytes induced by excessive alcohol consumption
por: Shiba, Shunsuke, et al.
Publicado: (2021)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells
por: Murakami, Yuko, et al.
Publicado: (2018)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Hepatic Adenosine Triphosphate Reduction Through the Short‐Chain Fatty Acids–Peroxisome Proliferator‐Activated Receptor γ–Uncoupling Protein 2 Axis Alleviates Immune‐Mediated Acute Hepatitis in Inulin‐Supplemented Mice
por: Yamaguchi, Akihiro, et al.
Publicado: (2021)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2017)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Detection of bacterial DNA by in situ hybridization in patients with decompensated liver cirrhosis
por: Usui, Shingo, et al.
Publicado: (2017)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Prediction of Effect of Pegylated Interferon Alpha-2b plus Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Infection
por: Takayama, Tetsuro, et al.
Publicado: (2011)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Concurrent de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia after Thymectomy: A Case Report and Literature Review
por: Sakata, Rie, et al.
Publicado: (2022)

Prominent Steatosis with Hypermetabolism of the Cell Line Permissive for Years of Infection with Hepatitis C Virus
por: Sugiyama, Kazuo, et al.
Publicado: (2014)

Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites
por: Shigefuku, Ryuta, et al.
Publicado: (2021)

IL-22-Producing RORγt-Dependent Innate Lymphoid Cells Play a Novel Protective Role in Murine Acute Hepatitis
por: Matsumoto, Atsuhiro, et al.
Publicado: (2013)

IL-15-producing splenic B cells play pathogenic roles in the development of autoimmune hepatitis
por: Fujimori, Sota, et al.
Publicado: (2023)

Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial
por: Tang, Jieting, et al.
Publicado: (2020)

Cases with Refractory Ascites and a Delayed Response to Tolvaptan
por: Hagiwara, Satoru, et al.
Publicado: (2016)

Surgical Treatment of Cirrhotic Ascites
Publicado: (1927)

Ayurvedic management of cirrhotic ascites
por: Aswathy, G., et al.
Publicado: (2016)

Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites
por: Huang, Lin-Lin, et al.
Publicado: (2014)

Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier
por: Mizuno, Shinta, et al.
Publicado: (2013)

Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model
por: Tanabe, Norikazu, et al.
Publicado: (2017)

Comment on ‘Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites’
por: Ahmed, Furqan
Publicado: (2017)

Myeloid TLR4 signaling promotes post-injury withdrawal resolution of murine liver fibrosis
por: Takimoto, Yoichi, et al.
Publicado: (2023)

A Metabolomic Analysis of Cirrhotic Ascites
por: Beyoğlu, Diren, et al.
Publicado: (2022)

A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis
por: Bessho, Rieko, et al.
Publicado: (2022)

Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
por: Iwasa, Motoh, et al.
Publicado: (2019)

Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
por: Imai, Michitaka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1es73eeijhddji2ec3e1325ja9